BCAN was founded in 2005 and is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease.
BCAN is on the front-lines advocating for greater public awareness and increased funding for research to identify effective treatments and eventually, a cure for bladder cancer.
Each year, BCAN provides thousands of patients, caregivers and the medical community with the educational resources and support services they need to navigate their bladder cancer journey. BCAN works collaboratively with the medical and research professionals who are dedicated to the prevention, diagnosis and treatment of bladder cancer and empowers the patient community by allowing them to share experiences with others, and to participate in building awareness of the need for a cure.
Watch Dr. Stephanie Chisolm, Director of Education & Research at BCAN provide an overview of the Bladder Cancer Advocacy Network on Cure Connection.
Diane and her husband John Quale, a bladder cancer patient, launch the Bladder Cancer Advocacy Network (BCAN) with the goal of improving the national conversation about bladder cancer and advancing research to find better treatments.
The first Bladder Cancer Think Tank is held in Aspen, Colorado, with 35 medical professionals and survivors attending. Today over 200 urologists, oncologists, pathologists, social scientists, patient advocates and industry partners attend the only annual scientific meeting in North America dedicated to bladder cancer.
First edition of Bladder Cancer Basics for the Newly Diagnosed is printed. Over 250,000 copies have been distributed.
BCAN awards its first research grant.
First national Walk for Bladder Cancer is held in more than 25 communities across the country.
BCAN hosts the first bladder cancer Capitol Hill Day. Advocates from across the country discuss the importance of bladder cancer awareness and increased research funding with their legislators.
Senate Resolution designates May as Bladder Cancer Awareness Month.
BCAN launches the Bladder Cancer Genomics Consortium (BCGC). The BCGC’s ultimate goal is to provide the opportunity for every patient to be an exceptional responder to personalized therapy while advancing collaborative research to support the development of life-saving treatments for bladder cancer.
A bladder cancer diagnosis can be overwhelming and perhaps frightening—not just for the patient but for family and friends as well. There are many resources available for finding support and connecting with others impacted by bladder cancer.
John C. Quale
In June 2008, BCAN lost its co-founder and board member, John Quale, to bladder cancer. His death leaves a hole in our bladder cancer family but his life serves as motivation to continue our important work.